Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer
Status:
RECRUITING
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
This clinical trial is a single-arm, non-randomized, prospective phase II study.
The study aims to evaluate if the maintenance immunotherapy with cemiplimab in patients with AdrenoCortical Carcinoma (ACC), who obtained disease response or stabilization after first-line chemotherapy, may delay/prevent disease progression.
The study will be conducted at ASST Spedali Civili Hospital, Brescia - Italy.
Phase:
PHASE2
Details
Lead Sponsor:
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia